Efficacy and safety of resmetirom for the treatment of nonalcoholic steatohepatitis: a GRADE assessed systematic review and meta-analysis

医学 非酒精性脂肪性肝炎 荟萃分析 内科学 非酒精性脂肪肝 胃肠病学 脂肪性肝炎 梅德林 脂肪肝 疾病 政治学 法学
作者
Muhammad Talha,Mohammad Haris Ali,Zain Ali Nadeem,Umar Akram,Praveen Bharath Saravanan,Muhammad Hamza Awais Khalid
出处
期刊:European Journal of Gastroenterology & Hepatology [Lippincott Williams & Wilkins]
卷期号:37 (3): 247-256 被引量:1
标识
DOI:10.1097/meg.0000000000002892
摘要

There are no Food and Drug Administration (FDA)-approved treatment options for nonalcoholic steatohepatitis (NASH) which is a prevailing disease that leads to fibrosis, cirrhosis, or hepatocellular carcinoma. Hence, this systematic review and meta-analysis aims to determine the efficacy and safety of resmetirom, the first FDA-approved drug, for the treatment of NASH. A Grading of Recommendations, Assessment, Development, and Evaluation assessed systematic search of Cochrane Library , MEDLINE , Scopus , and Google Scholar database was conducted from inception till 31 March 2024. Meta-analyses were carried out in accordance with the PRISMA statement. Heterogeneity was determined to be significant if found above 50%. This meta-analysis encompasses three randomized clinical trials, including a total of 2231 patients. The findings show resmetirom's significant efficacy in several key outcomes, including improvement in fibrosis risk ratios, 1.67 [95% confidence intervals (CI), 1.26-2.20], reductions in liver fat content (95% CI, -39.58 to -23.5), and enhanced liver fibrosis score (95% CI, -0.37 to -0.13) along with improved levels of liver enzymes. Resmetirom was found to be associated with nausea and diarrhea. This is the first systematic review and meta-analysis to determine the safety and efficacy of resmetirom which showed significant positive results in fibrosis improvement, liver fat content, lipid profiles, and liver enzymes in comparison to placebo. Moreover, moderate side effects, such as diarrhea and nausea, were seen in few patients indicating a satisfactory safety profile.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
xyp_zjut应助体贴凌柏采纳,获得10
刚刚
量子星尘发布了新的文献求助50
刚刚
在水一方应助妍儿采纳,获得10
1秒前
蔺不平完成签到,获得积分10
2秒前
2秒前
qingxinhuo完成签到 ,获得积分10
2秒前
4秒前
科研通AI5应助枕星采纳,获得10
5秒前
小曾应助pakiorder采纳,获得10
11秒前
wxy完成签到,获得积分10
12秒前
分析完成签到 ,获得积分10
12秒前
hulin_zjxu完成签到,获得积分10
12秒前
桃紫完成签到,获得积分10
14秒前
小董不懂完成签到,获得积分10
15秒前
椰子完成签到,获得积分10
15秒前
沐沐溪三清完成签到,获得积分10
15秒前
16秒前
刘丰完成签到 ,获得积分10
18秒前
郑桂庆完成签到 ,获得积分10
19秒前
zhang完成签到 ,获得积分10
19秒前
yuchen完成签到,获得积分10
20秒前
喜悦的水云完成签到 ,获得积分10
20秒前
21秒前
zhaokunfeng完成签到,获得积分10
21秒前
Y123发布了新的文献求助10
21秒前
wu完成签到,获得积分10
21秒前
高高诗柳完成签到 ,获得积分10
21秒前
王金豪完成签到,获得积分10
21秒前
LSS完成签到,获得积分10
21秒前
榜一大哥的负担完成签到 ,获得积分10
22秒前
Lucas应助qi0625采纳,获得10
22秒前
顾矜应助以筱采纳,获得10
23秒前
景清完成签到,获得积分10
23秒前
细心香烟完成签到 ,获得积分10
23秒前
hu完成签到 ,获得积分10
23秒前
HQ完成签到,获得积分10
23秒前
24秒前
水清木华完成签到,获得积分10
24秒前
25秒前
miao完成签到,获得积分20
25秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038368
求助须知:如何正确求助?哪些是违规求助? 3576068
关于积分的说明 11374313
捐赠科研通 3305780
什么是DOI,文献DOI怎么找? 1819322
邀请新用户注册赠送积分活动 892672
科研通“疑难数据库(出版商)”最低求助积分说明 815029